(click on the image above to view the video)

This video was recorded at the IMF Satellite Symposium that took place at the April 2019 Oncology Nursing Society’s annual meeting. It is the second in a three-part series on myeloma nursing. In this segment, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Taussig Cancer Insitute, Cleveland Clinic - Cleveland) and Sandra Rome RN, MN, AOCN, CNS discuss newly diagnosed multiple myeloma, response, bone health, renal health, minimal residual disease, survivorship care, relapsed myeloma, multiple therapeutic options, and immunotherapy considerations.


Full Video

Topics Covered:

This activity is supported by educational grants provided by Takeda Oncology, Celgene Corporation, Karyopharm Therapeutics Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Previous Post
Multiple Myeloma Background, Shared Decision Making, and Smoldering MM Research Update
Next Post
Relapsed Myeloma, Treatment for Relapsed Myeloma, Drugs in Development, Knowledge Post-Test

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.